8-K: NextCure Announces First Quarter 2025 Financial Results and Business Update

NextCure reports progress on its LNCB74 clinical trial and provides financial results for Q1 2025, with cash runway expected into the second half of 2026.

Summary

• NextCure announced its first quarter 2025 financial results and provided a business update on May 1, 2025.
• The company is progressing with the Phase 1 trial of LNCB74 (B7-H4 ADC) and has completed cohort 2 in April 2025.
• NextCure plans to initiate backfill cohorts in the second half of 2025 and expects to provide a proof of concept data readout in the first half of 2026.
• As of March 31, 2025, NextCure had $55.9 million in cash, cash equivalents, and marketable securities.
• The company expects these funds to be sufficient to fund operations into the second half of 2026.
• Research and development expenses for the quarter were $7.9 million, compared to $11.4 million for the same period in 2024.
• General and administrative expenses were $3.7 million, compared to $4.4 million for the same period in 2024.
• The net loss for the quarter was $11.0 million, compared to a net loss of $17.1 million for the same period in 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is progressing with its clinical trial and has a cash runway into the second half of 2026. However, it is still operating at a loss and faces risks associated with clinical development and funding.

Positives

• NextCure is making progress in its clinical trial for LNCB74.
• The company has a cash runway into the second half of 2026.
• Research and development expenses have decreased.
• General and administrative expenses have decreased.
• The net loss has decreased compared to the same period last year.

Negatives

• The company is still operating at a loss, with a net loss of $11.0 million for the quarter.
• Cash reserves decreased by $12.8 million during the quarter.

Risks

• Positive preclinical results may not be predictive of clinical trial results.
• NextCure has a limited operating history and no approved products.
• The company has a history of significant losses.
• NextCure needs to obtain additional financing.
• Clinical development, marketing approval, and commercialization are subject to risks.
• The company's ability to maintain its Nasdaq listing is at risk.
• NextCure is dependent on key personnel.

Future Outlook

NextCure expects its current financial resources to be sufficient to fund operating expenses and capital expenditures into the second half of 2026.

Management Comments

• With our LNCB74 antibody-drug conjugate (ADC) program completing cohort 2 in April 2025, we are progressing as planned through the dose escalation portion of the Phase 1 study, said Michael Richman, NextCures president and CEO.
• We expect to be in a position to initiate backfill cohorts in the second half of the year with 10 active investigator sites, and an additional 3 sites projected to be onboard in May 2025.
• We plan to provide a proof of concept data readout in the first half of 2026.

Industry Context

NextCure is focused on developing novel therapies for cancer, particularly antibody-drug conjugates (ADCs), which are a growing area of interest in the biopharmaceutical industry.

Comparison to Industry Standards

• It is difficult to compare NextCure directly to industry standards without knowing the specific stage and type of their lead compound, LNCB74.
• However, other clinical-stage biotech companies developing ADCs, such as ImmunoGen and Seagen (now part of Pfizer), serve as benchmarks.
• ImmunoGen's Elahere, an ADC targeting FRα, achieved FDA approval for ovarian cancer, demonstrating the potential of this therapeutic approach.
• Seagen's portfolio of ADCs, including Adcetris and Padcev, highlights the commercial success that can be achieved with successful ADC development.
• NextCure's cash runway into the second half of 2026 is a critical factor, as many biotech companies face challenges in securing funding for long-term development.
• Companies like NextCure are often compared to peers based on their cash burn rate, clinical trial progress, and potential market opportunity for their lead compounds.

Stakeholder Impact

• Shareholders: The progress of the LNCB74 trial and the company's financial stability are important for shareholder value.
• Employees: The company's restructuring in 2024 may have impacted employees, but the current focus is on advancing clinical programs.
• Patients: The development of new cancer therapies could potentially benefit patients who do not respond to current treatments.

Next Steps

• Initiate backfill cohorts for the LNCB74 study in the second half of 2025.
• Provide a proof of concept data readout for LNCB74 in the first half of 2026.
• Seek partnering opportunities for preclinical non-oncology programs NC181 and NC605.

Key Dates

Keywords

NextCure, LNCB74, B7-H4 ADC, clinical trial, financial results, research and development, net loss, cash runway, oncology, biopharmaceutical